We leverage our leading expertise and technology to develop novel small molecule therapeutics that can provide patients suffering from genetically defined cancers with prospects of a longer and healthier life.
By 2026, Beactica will be a clinical-stage precision oncology company. As we continue to innovate, we will expand our therapeutic pipeline to meet patient needs in the ever-evolving landscape of cancer drug development. We will also continue to build mutually beneficial industry partnerships that drive progress in the field of small molecule cancer therapeutics.
Sign up for the Beactica newsletter to receive our latest news and updates